title: [Chronic kidney disease and dyslipidaemia].
abstract: Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and mortality presented by these patients. In this review, an assessment is made of the lipid-lowering therapeutic measures required to achieve to recommended objectives, by adjusting the treatment to the progression of the disease and to the characteristics of the patient. In CKD, it seems that an early and intensive intervention of the dyslipidaemia is a priority before there is a significant decrease in kidney function. Treatment with statins has been shown to be safe and effective in decreasing LDL-Cholesterol, and in the reduction of cardiovascular events in individuals with CKD, or after renal transplant, although there is less evidence in the case of dialysed patients.
authors.affiliation: Centro de Salud Palleter, Castellón, España. Electronic address: pascual_vic@gva.es.
authors.forename: Vicente
authors.initials: V
authors.lastname: Pascual
authors.affiliation: Centro de Salud de Repelega, Osakidetza, Portugalete, Bizkaia, España.
authors.forename: Adalberto
authors.initials: A
authors.lastname: Serrano
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Servicio de Endocrinología, Hospital Clínico Universitario, Universitat de València, Valencia, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Ascaso
authors.affiliation: Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, España.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.affiliation: Unidad de Lípidos, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Universitat de Barcelona, CIBERobn-ISCIII, Barcelona, España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Millán
authors.affiliation: Servicio de Medicina Interna, Hospital Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó
authors.affiliation: Servicio de Nefrología, Hospital Clínic, Universitat de Barcelona, Red de Investigación Cardiovascular (RIC), Barcelona, España.
authors.forename: Aleix
authors.initials: A
authors.lastname: Cases
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood; D018450:Disease Progression; D050171:Dyslipidemias / Q000150:complications* / Q000628:therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000628:therapy; D017582:Renal Replacement Therapy / Q000379:methods; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Chronic kidney disease; Dislipidemia; Dyslipidemia; Enfermedad renal crónica; Estatinas; Statins